About Products & Pipeline Partnering Investors & News Blog Investors Investor Relations INVESTOR OVERVIEW STOCK INFORMATION Stock Quote Stock Chart Historic Stock Lookup Analyst Coverage Transfer Agent Form 8937 NEWS RELEASES COMPANY STATEMENTS EVENTS & PRESENTATIONS SEC FILINGS STOCKHOLDER MEETINGS AND PROXY MATERIALS CORPORATE GOVERNANCE CONTACT JAGUAR IR NEWS RELEASES Keyword Search Webcast Jaguar Health - Investor Conference Call Aug 13, 2020 at 8:30 AM EDT Date Title 11/19/21 Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients 11/17/21 Jaguar Health Reports 2021 Third Quarter Financial Results 11/16/21 Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager 11/15/21 Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time 11/10/21 Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates 11/08/21 Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer 11/02/21 Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch 11/01/21 The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed 10/29/21 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/25/21 Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing 10/07/21 Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A. 09/30/21 Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award 09/27/21 Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021 09/23/21 Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs 09/16/21 REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time 09/15/21 Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency 09/14/21 Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market 09/09/21 Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director 09/03/21 Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split 09/03/21 Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders 08/23/21 Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting 08/19/21 Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe 08/17/21 Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea 08/13/21 Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results 08/10/21 Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time 08/10/21 Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates 08/06/21 Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote 07/28/21 REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates 07/26/21 Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates 07/23/21 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 07/19/21 Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing 07/14/21 Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients 07/09/21 Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote 06/23/21 Jaguar Health Set to Join Russell Microcap Index 06/11/21 Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote 06/04/21 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 06/02/21 REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern 06/01/21 Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU 06/01/21 Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC 05/26/21 Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer 05/20/21 Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting 05/19/21 Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community 05/18/21 Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs 05/17/21 Jaguar Health, Inc. Reports 2021 First Quarter Financial Results 05/14/21 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 05/14/21 Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote 05/11/21 Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates 04/29/21 Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan 04/29/21 Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting 04/21/21 REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary 04/19/21 Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary 04/15/21 Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs 04/14/21 Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting 04/08/21 Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC 04/06/21 Jaguar Health Promotes Carol Lizak to Chief Financial Officer 04/02/21 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 03/31/21 Jaguar Health Reports 2020 Financial Results and Business Updates 03/30/21 Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary 03/22/21 Jaguar Health Announces Winner of International Day of Forests Contest 03/15/21 Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy 03/09/21 Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream 03/05/21 Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream 02/23/21 Jaguar Health Launches Website for Napo EU 02/19/21 Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU 02/18/21 Jaguar Health Signs Memorandum of Understanding with the Lead Sponsor of the Planned Dragon SPAC Pursuing Listing on AIM Italia, Providing the Dragon SPAC with Exclusivity for a Proposed Business Combination with Napo EU 02/09/21 Noted Natural Products Industry Veteran Dr. Nigel Gericke Joins Scientific Strategy Team for Jaguar Health’s Recently Launched Mental Health Entheogen Therapeutics Initiative 02/03/21 Jaguar Health's Chief of Sustainable Supply, Dr. Steven King, an Ethnobotanist, to Discuss Crofelemer Development on February 4th at 2 PM Eastern as Part of the American Botanical Council's Sustainable Herbs Program Webinar Series 01/26/21 REMINDER: Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time to Provide Updates Regarding the Potential Merger of Napo EU, the Company’s Anticipated Subsidiary in Italy 01/22/21 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01/22/21 Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement 01/21/21 Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time to Provide Updates Regarding the Potential Merger of Napo EU, the Company’s Anticipated Subsidiary in Italy 01/20/21 Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher 01/15/21 Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast 01/13/21 Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher 01/13/21 Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules 01/12/21 Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference 01/11/21 Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ COVID-19 Recovery Patients in Europe 01/06/21 Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera 12/23/20 Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream 12/22/20 Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar 12/15/20 REMINDER: Jaguar Health to Host Investor Call Thursday, December 17, 2020 to Allow Management to Review Developments Since the Definitive Proxy Statement for the Company’s December 9, 2020 Special Meeting of Stockholders Was Filed 12/10/20 Jaguar Health Announces Adjournment of Its Special Meeting of Stockholders Until Tuesday, December 22, 2020 12/07/20 Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020 12/04/20 Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 11/30/20 Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients 11/24/20 Jaguar Health Announces Release of Podcast Interview with The Wall Street Resource 11/16/20 Jaguar Health, Inc. Reports 2020 Third Quarter Financial Results 11/10/20 Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates 10/29/20 Jaguar Health Receives Positive Nasdaq Listing Determination 10/20/20 Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer" 10/16/20 Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 10/15/20 Napo Pharmaceuticals, a Subsidiary of Jaguar Health, Launches Web-based NapoCares Platform to Enhance Patient Access to Mytesi 10/14/20 Jaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs & Quality Assurance 10/13/20 Jaguar Health Provides Updates Regarding Company Capitalization Strategy 10/07/20 Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy 10/06/20 Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications 10/02/20 Jaguar Health's Mental Health Entheogen Therapeutics Initiative Targets Plant-based Candidate Compound for Possible Schizophrenia and Psychoses Indications 10/01/20 Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million 09/28/20 Jaguar Health Subsidiary Napo Pharmaceuticals Sponsoring 2020 National Trans Visibility March 09/24/20 Jaguar Health to Host Exclusive Virtual Educational Event “Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer” 09/16/20 Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative 09/11/20 Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16 09/10/20 Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 09/03/20 Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants 09/02/20 Jaguar Health Completes Transactions that Increase Stockholders' Equity Above $5,000,000 08/19/20 Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi) 08/18/20 Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs 08/14/20 Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into a Second Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 08/13/20 Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results 08/11/20 Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates 08/06/20 Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea 07/22/20 Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 07/22/20 Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera 07/21/20 Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders 07/20/20 FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs 07/06/20 Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea 07/02/20 Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs 06/29/20 Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter an Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020 06/23/20 Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 06/23/20 Preclinical Study Demonstrating Symptomatic Relief of Diarrhea in Dogs Receiving Neratinib in Combination with Crofelemer (Mytesi) Presented at American Association for Cancer Research Virtual Annual Meeting 06/22/20 On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals 06/19/20 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 05/28/20 Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs 05/26/20 Jaguar Health Sustainability Leader Interviewed on Foodie Pharmacology Podcast 05/22/20 Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds 05/20/20 Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug Product 05/15/20 Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of Stockholders 05/15/20 Jaguar Health, Inc. Reports 2020 First Quarter Financial Results 05/13/20 Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC 05/12/20 Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates 05/12/20 Jaguar Health Clears Important Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Exercise-Induced Diarrhea (EID) in Dogs 04/16/20 Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate 04/06/20 Jaguar Health Reports 2019 Financial Results and Business Updates 04/03/20 Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates 04/02/20 Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support Program 04/01/20 Jaguar Health Clears Key Regulatory Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs 03/12/20 Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. Eastern 03/05/20 Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream 02/20/20 Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award 02/06/20 Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern 01/08/20 Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome 12/16/19 Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients 12/10/19 Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern 11/21/19 Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern 11/20/19 Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine 11/14/19 Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results 11/14/19 Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients 11/13/19 Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy 11/12/19 Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates 10/30/19 Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. 10/23/19 Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea 10/22/19 Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI 10/10/19 Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China 10/04/19 Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer 10/01/19 Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs 09/30/19 Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application 09/26/19 Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern 09/24/19 Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea 09/23/19 Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use 09/19/19 Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York 09/18/19 Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer 09/16/19 Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico 09/09/19 Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel 08/26/19 Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs 08/22/19 Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern 08/20/19 Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director 08/19/19 Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy 08/16/19 Jaguar Health Appoints Carol Lizak Chief Accounting Officer 08/14/19 Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results 08/07/19 Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website 08/02/19 Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea 07/26/19 Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today 07/23/19 Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option 07/19/19 Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering 07/15/19 Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million 07/11/19 Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea 06/28/19 Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million 06/26/19 Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome 06/19/19 Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs 06/18/19 Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors 06/11/19 Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication 06/06/19 Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split 06/05/19 Jaguar Health CEO and Board Members Invest in Bridge Financing 06/03/19 Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 05/29/19 Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet 05/24/19 Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders 05/24/19 Jaguar Health, Inc. Reports 2019 First Quarter Financial Results 04/25/19 Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief 04/10/19 Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results 04/02/19 Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi 03/28/19 Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi 03/20/19 Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs 03/05/19 Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders 02/25/19 Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019 01/24/19 With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product 01/22/19 Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale 01/09/19 Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes 01/07/19 Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates 01/03/19 Jaguar Health to Present at Biotech Showcase 2019 in San Francisco 01/02/19 Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance 12/06/18 Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer 11/14/18 Jaguar Health, Inc. Reports Third-Quarter 2018 Results 11/13/18 Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th 10/29/18 Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th 10/24/18 Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida 10/02/18 Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering 09/24/18 Knight Therapeutics and Jaguar Health Announce Strategic Partnership 07/24/18 New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time 07/16/18 Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference 07/12/18 Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates 06/28/18 Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product 06/20/18 Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors 06/18/18 Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors 06/12/18 Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients 06/01/18 Jaguar Health, Inc. Announces 1-for-15 Reverse Stock Split 05/29/18 Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals 05/18/18 Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders 05/15/18 ''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea 04/19/18 Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea 04/10/18 Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi 04/09/18 Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV 04/02/18 Jaguar Health Appoints Jonathan B. Siegel to Board of Directors 03/26/18 Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi 03/08/18 FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs 03/02/18 Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program 01/22/18 Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017) 01/18/18 Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results 01/18/18 Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim 12/14/17 Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses 12/12/17 New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence 12/01/17 Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017 12/01/17 Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline 11/27/17 Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC 11/20/17 Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals 11/15/17 Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug 11/14/17 Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million 11/14/17 Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time 11/09/17 Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time 11/08/17 Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi 11/07/17 Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals 11/01/17 Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug 10/26/17 Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS 10/19/17 Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug 10/18/17 Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA) 09/29/17 Jaguar Health Prices $4.25 Million Public Offering of Common Stock 09/28/17 Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napo’s FDA-Approved Human Drug, to Support Upcoming National Sample Campaign 09/25/17 Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar’s Global Commercial Control of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug 09/20/17 FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication 09/18/17 Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors 09/18/17 Jaguar Health Announces Proposed Public Offering of Common Stock 09/15/17 Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets 09/12/17 New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients 08/16/17 Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger 08/07/17 Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome 07/31/17 The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective 07/27/17 Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger 07/24/17 New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment 07/18/17 Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal 07/06/17 Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc. 06/27/17 Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science 06/14/17 Jaguar Animal Health’s Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle 06/07/17 Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf 06/05/17 Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs 05/25/17 Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present at the Southern California Investment Forum May 31, 2017 in Los Angeles 05/24/17 Napo Pharmaceuticals’ New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDS 05/10/17 Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory Board 04/28/17 Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf 04/06/17 Jaguar and Napo Issue Commercial Updates 03/31/17 Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement 03/28/17 Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguar’s Drug Product Candidate for Equine Gastric Ulcer Syndrome 03/14/17 Jaguar Animal Health Seeks MUMS Designation for Canalevia for Exercise-Induced Diarrhea in Dogs 03/03/17 Jaguar Animal Health to Participate in 29th Annual ROTH Conference the Week of March 13th in Orange County, California 02/28/17 Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for Mytesi 02/14/17 Study Supporting Herd-wide Reduction in Incidence and Severity of Diarrhea With Prophylactic Use of Neonorm Calf Published in Journal of Dairy Science 02/08/17 Jaguar Animal Health Enters Binding Agreement of Terms to Merge with Napo Pharmaceuticals 02/02/17 Jaguar Animal Health Begins Entry Into Organic Market With Neonorm Calf 01/31/17 Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of Canalevia 01/05/17 Jaguar Animal Health to Participate in Biotech Showcase 2017 Week of January 9th in San Francisco 12/19/16 Jaguar Animal Health Appoints Dr. Ari Azhir to Board of Directors 12/12/16 Jaguar Animal Health and Henry Schein, Inc. Sign Exclusive Distribution Agreement for Neonorm Foal 12/09/16 Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual Convention 11/23/16 Jaguar Animal Health Announces Private Placement of Common Stock and Warrants 11/14/16 Jaguar Animal Health Issues Racing Data Summary for Horses Participating in the Company’s Recently Completed Dose Determination Study for its Drug Product Candidate for Equine Gastric Ulcer Syndrome 10/18/16 Jaguar Animal Health Announces Final Topline Results for Proof-of-Concept Study for Secretory Diarrhea in Dogs 10/06/16 Jaguar Animal Health and Napo Pharmaceuticals Announce Details for Proposed Merger 09/07/16 Jaguar Animal Health Signs Exclusive Distribution Agreement for Croton lechleri Botanical Extract for Pigs and Dairy Cattle in the Chinese Marketplace 09/01/16 Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary Medicine 07/25/16 Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets 06/30/16 Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer 06/17/16 Jaguar Animal Health Announces Positive Topline Results of University Study of Second-Generation Formulation of Neonorm Calf and Commercialization Strategy Updates 06/09/16 Jaguar Animal Health Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC 05/04/16 Jaguar Animal Health Initiates Dose Determination Study with the Target Commercial Paste Formulation of SB-300, the Company’s Drug Product Candidate for Treatment of Equine Gastric Ulcer Syndrome 04/19/16 SB-300, Jaguar’s Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing Guidelines 04/13/16 Jaguar Animal Health Obtains Protocol Concurrence From FDA for Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs 04/06/16 Jaguar Animal Health Appoints John Micek III to Board of Directors 02/22/16 Jaguar Animal Health Appoints Dr. Philippe Brianceau as Chief Veterinary Officer 02/16/16 Jaguar’s SB-300 Drug Product Candidate in Development 02/09/16 Jaguar Animal Health, Inc. Announces Closing of Public Offering; Secures Funding Through Anticipated Launch of First Prescription Drug Product Candidate 02/03/16 Jaguar Animal Health, Inc. Prices 2,000,000 Common Share Offering 01/28/16 Jaguar Animal Health Reports Topline Findings for its Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses 01/07/16 Jaguar Animal Health Initiates University Study to Further Investigate Possible Prophylactic and Prebiotic Benefits of a Second-Generation Formulation of Neonorm in Dairy Calves 12/22/15 Jaguar Animal Health Initiates Pivotal Field Study to Evaluate Safety and Effectiveness of Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs 12/21/15 Jaguar Animal Health Announces Positive Results in University Pilot Safety Study of Crofelemer in Horses 12/18/15 Jaguar Animal Health Announces Positive Results of Investigator-Initiated Follow-up Neonorm Study in Foals 12/16/15 Jaguar Animal Health Appoints Karen Wright as Chief Financial Officer 12/15/15 Jaguar Animal Health Completes Enrollment for Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses 12/03/15 Jaguar Animal Health Initiates University Pilot Safety Study to Evaluate Use of Crofelemer for the Treatment of Diarrhea Associated with Acute Colitis in Horses 11/23/15 Jaguar Animal Health to Present at the 2015 LD Micro Conference on December 3rd in Los Angeles 11/16/15 Jaguar Animal Health Announces Positive Results from Proof-of-Concept Study of Neonorm in Foals 11/05/15 Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses 10/27/15 University Study Supports Benefit of Jaguar Animal Health’s Neonorm Calf on Intestinal Microbiome in Pre-weaned Dairy Calves 10/26/15 U.S. Patent and Trademark Office Issues Notices of Allowance in Two Pending NP-500 Patent Applications Licensed Exclusively by Jaguar Animal Health for Veterinary Use 10/26/15 Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York City 10/15/15 Jaguar Animal Health Signs Crofelemer Formulation Development and Manufacturing Contract with Patheon 10/07/15 Jaguar Animal Health Completes Second Neonorm Field Study Indicating Beneficial Effect of Product on Pre-Wean Weight Gain & Normalization of Stool Formation in Dairy Calves Beyond Current Standard of Care 10/02/15 Jaguar Animal Health to Present at the Aegis Capital 2015 Growth Conference 09/28/15 Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd. 09/25/15 Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate Safety, Tolerability & Efficacy of Neonorm in Foals 09/02/15 Study Evaluating Effect of Jaguar Animal Health’s Neonorm on Diarrhea in Newborn Dairy Calves Published in Journal of Dairy Science 08/25/15 Jaguar Animal Health to Attend the 2015 KC Animal Health Investment Forum 08/19/15 Jaguar Animal Health Secures Debt Financing 08/19/15 Jaguar Animal Health Submits All Required Major Technical Sections of New Animal Drug Application for Canalevia 07/16/15 KCSA Strategic Communications to Lead Investor Relations Program for Jaguar Animal Health 07/07/15 Jaguar Animal Health Appoints Dr. Victoria Lewis as Chief of Clinical Development 07/01/15 Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of Canalevia 06/30/15 Jaguar Animal Health, Inc. Added to Russell Microcap Index 06/09/15 Jaguar Animal Health Field Study Confirms Beneficial Effect of Neonorm on Average Daily Weight in Calves 06/03/15 Jaguar Animal Health Appoints Industry Expert Folkert Kamphuis to Board of Directors 05/13/15 Jaguar Animal Health, Inc. Announces Pricing of Initial Public Offering 03/04/15 Jaguar Animal Health Files Two Provisional Patent Applications, Deepening its Pipeline of Proprietary Gastrointestinal Products for Animals 02/26/15 Jaguar Animal Health Signs Agreement with Latin America’s Largest Veterinary Biotechnology Company 02/19/15 Jaguar Animal Health Announces Outcome of Canine Proof-of-Concept Study for Canalevia 02/10/15 Jaguar Animal Health Files Ninth Investigational New Animal Drug Application 02/05/15 Jaguar Animal Health Signs Distribution Agreement with Vedco and Kicks off National Neonorm Calf Marketing Campaign 12/22/14 Jaguar Animal Health Initiates Filing of Its First New Animal Drug Application with FDA 12/04/14 Jaguar Animal Health Completes Equine Study for Safety & Palatability of Neonorm™ Foal Gastrointestinal Product 11/21/14 Jaguar Animal Health Appoints Former Merial Executive to Head Regulatory Affairs 09/29/14 Jaguar Animal Health, Inc. Launches First Product, Neonorm™ Calf, at World Dairy Expo 09/17/14 Jaguar Animal Health, Inc. Files Eighth Investigational New Animal Drug Application 07/08/14 Jaguar Animal Health Names VP, Commercial Operations 03/03/14 Jaguar Files INADAs for Diarrhea in Companion Animals and Horses 02/05/14 Jaguar Announces Initial Close of Series A Round 01/14/14 Drug Application For Chemo-induced Diarrhea In Dogs Moving Forward Tools Print Page RSS Feeds Email Alerts © Copyright 2021 Jaguar Health Contact Us | Careers | Legal Notice | Privacy Policy | Social Media Policy | Website Accessibility Feedback Email | Web Accessibility Feedback Form |